doi: 10.1161/01.RES.0000126574.61061.25
© 2004 American Heart Association, Inc.
Reviews |
The Dystrophin Glycoprotein Complex
Signaling Strength and Integrity for the Sarcolemma
From the Department of Molecular Genetics and Cell Biology (K.A.L.), Department of Medicine (R.K., E.M.M.), and Department of Human Genetics (E.M.M.), University of Chicago, Ill.
Correspondence to E.M. McNally, MD, PhD, University of Chicago, 5841 S Maryland, MC6088, Room G611, Chicago, IL 60637. E-mail emcnally{at}medicine.bsd.uchicago.edu
This Review is part of a thematic series on Myocyte Intra- and Extrasarcomeric Structural Proteins, which includes the following articles:
The Giant Protein Titin: A Major Player in Myocardial Mechanics, Signaling, and Disease
The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma
Cardiac Myosin Binding Protein C: Its Role in Physiology and Disease
David Kass Editor
 |
Abstract |
|---|
 Top Abstract IntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
The dystrophin glycoprotein complex (DGC) is a specialization of cardiac and skeletal muscle membrane. This large multicomponent complex has both mechanical stabilizing and signaling roles in mediating interactions between the cytoskeleton, membrane, and extracellular matrix. Dystrophin, the protein product of the Duchenne and X-linked dilated cardiomyopathy locus, links cytoskeletal and membrane elements. Mutations in additional DGC genes, the sarcoglycans, also lead to cardiomyopathy and muscular dystrophy. Animal models of DGC mutants have shown that destabilization of the DGC leads to membrane fragility and loss of membrane integrity, resulting in degeneration of skeletal muscle and cardiomyocytes. Vascular reactivity is altered in response to primary degeneration in striated myocytes and arises from a vascular smooth muscle cell–extrinsic mechanism.
Key Words: dystrophin • sarcoglycan • membrane • cardiomyocyte • skeletal muscle
|
Introduction |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Striated muscle contraction requires precise and coordinated activity of both the nervous and somatic systems, from excitation of individual myofibers at the neuromuscular junction to the ATP-regulated power stroke of myosin. Muscle contraction in both heart and skeletal muscle results in cellular deformation and shortening. Throughout this process, the contractile machinery inside the myofibers must remain intimately connected with the membrane and extracellular matrix. Without this association, movement would be improperly transmitted and myocytes would risk damage to their membranes. One function of the dystrophin glycoprotein complex (DGC) is to provide a strong mechanical link from the intracellular cytoskeleton to the extracellular matrix. The DGC is composed of transmembrane, cytoplasmic, and extracellular proteins. With the emergence of data on the numerous and diverse components of the complex and how they interact with one another, it has become increasingly clear that the DGC holds both structural and signal transduction properties. Known components of the DGC include dystrophin, sarcoglycans, dystroglycan, dystrobrevins, syntrophins, sarcospan, caveolin-3, and NO synthase (Figure 1). These proteins are found in differing combinations depending on muscle type (Table).
|
|
|
Dystrophin |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Mutations in the X-linked dystrophin gene produce Duchenne muscular dystrophy (DMD), the milder Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM). Cardiomyopathy is frequent in both DMD and BMD; subjects with XLDCM differ in that they have little to no skeletal muscle disease. The large size of the dystrophin gene contributes significantly to its high rate of spontaneous mutation. The 79 exons that encode the 14-kb cDNA span over 2.4 MB of chromosome Xp21 (Figure 2). Several amino-terminally truncated forms of dystrophin are generated by the use of internal tissue-specific promoters.1–3 The internal promoters drive expression of mRNAs encoding smaller dystrophin products with a distinct tissue-specific distribution. The small 71-kDa carboxyl-terminal form, referred to as Dp71, is broadly expressed. Mutations that preferentially affect dystrophin mRNA expression in cardiac but not skeletal muscle provide one molecular explanation for cardiomyopathy without skeletal muscle involvement, as seen in XLDCM.4,5 However, not all cases of XLDCM can be explained in this manner. For example, point mutants have been described in XLDCM, suggesting that the function of dystrophin may differ between cardiac and skeletal muscle.6,7 Supporting this, DGC proteins are present in T-tubule invaginations that project internally into cardiomyocytes. In skeletal muscle, the DGC is restricted to the plasma membrane, with no internal pattern.8,9 Therefore, this differential cellular localization may indicate additional functions for the DGC in cardiomyocytes. Alternatively, protective mechanisms may be variably present that keep cardiac muscle from undergoing degeneration at the same rate as skeletal muscle.
|
|
Dystrophin Has Four Functional Domains |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
The amino-terminus of dystrophin contains a calponin-like actin binding domain with homology to other actin binding proteins, such as ß-spectrin and
-actinin. The amino-terminal actin binding domain is responsible for anchoring dystrophin to cytoskeletal, filamentous 
-actin.10 The central rod domain of dystrophin consists of 24 spectrin-like repeats. Like other spectrin repeats, three helix bundles align to form each repeat unit and provide structural stiffness. Flexibility of the rod region is thought to derive from breaks in the spectrin repeat pattern at four hinge regions. Within the rod region, spectrin repeats 11 through 17 constitute a second site for binding -actin, and this site differs considerably in the dystrophin homolog utrophin.11 At the carboxyl-terminus, the cysteine-rich region interacts with the intracellular portion of the transmembrane protein ß-dystroglycan and anchors dystrophin to the sarcolemma. The extreme carboxyl-terminal region is -helical in nature and mediates its interaction with the syntrophins.12–14 In the absence of dystrophin, the transmembrane DGC elements are unstable and are reduced at the sarcolemma. Skeletal and cardiac muscle that lacks full-length dystrophin and the DGC is abnormally susceptible to damage from contraction. In skeletal muscle, enhanced myofiber damage occurs with eccentric contraction. Contraction of a lengthened muscle lacking dystrophin rapidly loses peak force with rapid, successive contraction.15 In the heart, aortic banding experiments performed on the dystrophin-deficient mdx mouse similarly result in accelerated cardiac damage.16 These studies demonstrate the essential role of dystrophin and the DGC in protecting the plasma membrane against contraction-induced damage.
The mdx mouse is a model for DMD that carries a naturally occurring point mutation in the dystrophin gene that results in a premature stop codon.17 There is a complete loss of dystrophin protein expression, with the exception of rare revertant fibers that arise from exon skipping to restore dystrophin and DGC protein expression. Compared with human DMD, the phenotype of the mdx mouse follows a less severe course, especially with respect to cardiomyopathy.18 Creatine phosphokinase levels are elevated,19 and the membrane is abnormally permeable to vital tracers such as Evans blue dye (EBD).20,21 At the molecular level, the loss of dystrophin results in destabilization of the rest of the DGC, including the sarcoglycan complex. Thus, the mechanical link between the sarcolemma and the extracellular matrix is compromised, providing a mechanism for the plasma membrane leakiness. Intracellular levels of Ca2+ are generally elevated.19
Antibodies to specific regions of dystrophin have been useful to identify that disrupted dystrophin is a feature of the decompensated cardiomyopathic heart.22 Antibodies directed against epitopes at dystrophin’s amino-terminus have a greatly reduced staining pattern in core samples taken from patients with heart failure undergoing ventricular assist device implantation. In this setting, epitopes recognized in dystrophin’s rod and carboxyl-terminus appear intact and normally localized. Moreover, improved remodeling provided by afterload reduction from ventricular assist device implantation is associated with restoration of the normal dystrophin pattern at the sarcolemma of cardiomyocytes.23 Disrupted dystrophin and its role in remodeling was noted in cardiomyopathic hearts of diverse etiologies. Dystrophin disruption is also important in viral cardiomyopathy.24 The enteroviral protease 2A specifically cleaves dystrophin in its rod portion, contributing to cardiomyocyte degeneration in Coxsackie virus infection. Interestingly, dystrophin deficiency also enhances enteroviral infection, because the DGC may play a role in propagating infection.25 Therefore, defects in dystrophin contribute to nongenetic forms of cardiomyopathy.
|
The Sarcoglycan Complex and Sarcospan |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
The six sarcoglycans,
, ß, 
, 
, , and the recently identified 
, copurify as a complex within the DGC (Figure 3). All are transmembrane-spanning glycoproteins with at least one glycosylation site. - and -sarcoglycan share high homology and are both type I transmembrane proteins. -, -, and -sarcoglycan are also highly related, and these three subunits likely resulted from multiple gene duplication events, because lower organisms have a single (//) sarcoglycan-like gene. These sarcoglycan subunits show weak homology to ß-sarcoglycan and are all type II transmembrane proteins. Although the precise function of the complex has remained somewhat elusive, investigations with -sarcoglycan–null and -sarcoglycan–null mice have helped define the role of the sarcoglycan complex.26–28 In the absence of -sarcoglycan, the remaining sarcoglycans cannot assemble in the endoplasmic reticulum. In contrast, with the loss of -sarcoglycan, assembly of -, ß-, and -sarcoglycan can still be detected but is greatly reduced. In sarcoglycan-null muscle, dystrophin remains localized at the plasma membrane and does not require sarcoglycan for normal distribution.26 However, the phenotype of striated myocyte membrane permeability defects and degeneration is present in sarcoglycan-null muscle, suggesting that sarcoglycan loss, as the common molecular feature, is the major mediator of membrane fragility in DGC mutants. Interestingly, -sarcoglycan–null muscle does not display contraction-induced damage.29
|
60% related.
Mutations in ß-sarcoglycan, like - and -sarcoglycan, can lead to muscular dystrophy associated with cardiomyopathy.30 Cardiac abnormalities, when present, are similar to what is observed in DMD.9,31 Mutations in -sarcoglycan have been described in human DCM patients without accompanying muscle disease.32 In this case, two different autosomal-dominant mutations in the -sarcoglycan gene associated with human DCM. One mutation, S151A, may function in a dominant-negative manner, whereas the second produces a single amino acid deletion in an isoform of -sarcoglycan that is highly expressed in the placenta. This isoform lacks the conserved cysteine residues that are a feature of ß-, -, -, and the major muscle form of -sarcoglycan, and its function in striated muscle is not well studied.33,34
Mice lacking sarcoglycan genes effectively model human mutations leading to muscular dystrophy and cardiomyopathy. A notable exception is -sarcoglycan–null mice that develop skeletal, but not cardiac, involvement.35 This difference may relate to compensation by the related -sarcoglycan sequence in cardiac muscle.36 Sarcoglycan-null mutant mice display the same membrane fragility features seen in mdx mice, and cardiac and skeletal muscle disease develop from independent processes.37 In the heart, the loss of sarcoglycan produces cardiomyopathy that is variably hypertrophic and may progress to dilated cardiomyopathy.38 As in skeletal muscle, sarcoglycan and dystrophin mutant cardiac muscle displays focal necrosis, and it was previously hypothesized that such focal necrosis was produced from vascular spasm.39 Supporting this, mice null for -sarcoglycan or ß-sarcoglycan display a disrupted vascular smooth muscle sarcoglycan complex and evidence for vascular spasm.27,40 Transgenic rescue of cardiomyocyte -sarcoglycan expression corrects not only cardiomyopathy but also vascular spasm.41 These studies demonstrate that a cardiomyocyte-intrinsic defect is responsible for cardiomyopathy in DGC mutant hearts. Additionally, these studies underscore a paradigm where cardiomyocyte degeneration leads to vascular spasm. Vascular spasm in these models is pathogenic, because reduction of vascular spasm limits cardiomyopathy progression.38,42
Sarcospan is a member of the tetraspanin family that associates tightly with the DGC and sarcospan.14,43,44 Sarcospan is a highly hydrophobic protein whose amino and carboxyl-termini each face the cytoplasm. In addition, the presence of the sarcoglycan complex is required for the stability of sarcospan at the plasma membrane. Sarcospan-null mice maintain the proper assembly of the entire DGC, showing normal muscle function and histology, serum creatine kinase levels, and impermeability of muscle fibers to EBD.45,46 The tetraspanin family is highly diverse, so additional sarcospan-like proteins may accommodate the loss of sarcospan. In other tissues, tetraspanins have been implicated in mediating integrin-signaling responses.47
|
Dystroglycan |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Dystroglycan forms an essential core of the DGC as it connects the cytoskeletal components of the DGC to the extracellular matrix.48 Dystroglycan is produced from a single gene and is posttranslationally cleaved to produce
and ß subunits. ß-dystroglycan is a single-pass transmembrane protein, and its carboxyl-terminus interacts with the cysteine-rich domain of dystrophin. ß-dystroglycan also binds to Grb2, providing a known signaling pathway for ß-dystroglycan.49 Caveolin-3 also interacts with ß-dystroglycan, and it may compete for the same binding site as dystrophin.50 The amino-terminus of ß-dystroglycan interacts with its extracellular binding partner -dystroglycan. -dystroglycan forms an important connection to the extracellular matrix through its interactions with the 2 chain of laminin 2. Thus, dystroglycan forges a link between the sarcolemma and the extracellular milieu.
Dystroglycan is found in nearly all cell types and is also expressed highly during development, although its posttranslational modifications may differ with cell and tissue type. Unlike the sarcoglycan subunits, dystroglycan exhibits O-linked glycosylation, and genetic studies have now implicated a novel class of genes in the posttranslational processing of -dystroglycan.51 Mutations in these genes lead to muscular dystrophy, abnormal central and peripheral nervous system function, as well as cardiomyopathy. Of these novel genes, the fukutin-related protein gene leads to a form of disease that is highly associated with cardiomyopathy.52 In common with these disorders is aberrant processing of -dystroglycan.
|
Syntrophin |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Syntrophin, first identified as a 58-KDa protein in the electric tissue of Torpedo, interacts directly with the carboxyl-terminus of both full-length and truncated forms of dystrophin.53,54 Three syntrophin forms exist, and each isoform contains two pleckstrin homology domains, a PH1 domain with an internal PDZ domain and a PH2 domain. Syntrophin binds to PIP2, neuronal NO synthase (nNOS), calmodulin, and Grb2.55–57,58 Recently, a link between syntrophin, the DGC, and downstream signaling was identified through Rac1 interactions. A putative signaling pathway was identified in which syntrophin acts as an adaptor for the signaling complex Grb2-Sos1.59
|
-Dystrobrevin
|
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
-Dystrobrevin shares significant homology with the cysteine-rich and carboxyl-terminal domains of dystrophin, although it lacks dystrophin’s actin binding and rod domains.60 Three isoforms of -dystrobrevin, derived from alternative splicing, are components of skeletal muscle DGC. Important motifs present in the longest isoform, -dystrobrevin-1, include the Ca2+-binding EF hand, zinc finger ZZ-domain, coiled-coil domain, and a tyrosine kinase substrate domain. The coiled-coil domains directly interact with dystrophin, and an upstream syntrophin binding site allows -dystrobrevin to interact with the syntrophins.61 -Dystrobrevin–null mice show a complete absence of nNOS at the sarcolemma despite the presence of other DGC components, such as ß-dystroglycan, - and ß-sarcoglycan, dystrophin, and syntrophin.62 nNOS is responsible for increasing cyclic GMP levels to reduce vasoconstriction of smooth muscle. -Dystrobrevin–null mice were unable to increase cyclic GMP levels on stimulation, suggesting that nNOS may be a downstream signaling mediator of -dystrobrevin.62 These mice display mild skeletal and cardiac muscle disease. A mutation in -dystrobrevin has been described in human left ventricular noncompaction with congenital heart disease.63 The mutation, found in exon 3, resulted in an amino acid change from proline to leucine and is predicted to alter the EF hand domain.64 |
Caveolin and NO Synthase |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Caveolin-3 is expressed only in striated muscle.65 Like other caveolin forms, caveolin-3 can oligomerize to form caveolae, small membrane invaginations that participate in membrane organization and uptake of small solutes. Caveolae are thought to be docking sites for signaling proteins, and it was recently shown that caveolin-3 is critical for the localization of src.66 The absence of caveolin-3 increases myofiber apoptosis.66 Caveolin binds directly to nNOS. In dystrophin-deficient skeletal muscle, nNOS is displaced from the plasma membrane, and this disruption mediates abnormal exercise-induced vasoconstriction.67,68 Moreover, muscle that expresses
-syntrophin deleted for the nNOS binding site has impaired vasoconstriction, confirming that nNOS membrane localization with the DGC is critical for vasoconstriction.69 The role of NOS may differ between the cardiac and skeletal muscle DGC. In cardiac muscle, it is endothelial NO synthase that participates in a complex with -sarcoglycan and -sarcoglycan.70 |
Costameric Arrangement of the DGC |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
In skeletal and cardiac muscle membranes, the DGC is concentrated over costameres.71,72 Costameres are transverse, rib-like structures that overlie the Z lines of the sarcomere (Figure 4). Focal adhesion proteins such as vinculin,
-actinin, ß1 integrin, and ß-spectrin are also costameric, but the exact relationship between these focal adhesion components and the DGC is not known. Costameres are thought to transmit mechanical force from the sarcomere to the sarcolemma, the extracellular matrix, and even surrounding fibers and require both outside-in and inside-out signaling.73 Dystrophin and other DGC proteins can also be detected, albeit in lesser amounts, between costameres overlying the M line.72
|
Mechanically skinned, or peeled, myofibers retain a costameric dystrophin lattice on their internal membrane surface.10 The cytoplasmic face of normal, peeled membrane contains dystrophin colocalized with cytoplasmic -actin; however, peeled membrane from dystrophin-deficient muscle no longer retained -actin. Dystrophin-deficient peeled membrane maintained some degree of costameric organization, because proteins such as vinculin, -actinin, ß-dystroglycan, and utrophin were all present. The presence of both -actin and dystrophin on normal fibers after stripping demonstrates that a mechanically strong linkage is present between dystrophin and cytoplasmic -actin. Interestingly, the costameric organization of dystrophin-positive myofibers is compromised in BMD.74 The disruption of the costameric arrangement may be the major initiating factor in the loss of membrane permeability that is a feature of both cardiac and skeletal muscle lacking sarcoglycan or dystrophin (Figure 5). The major integrin complex of cardiac and skeletal muscle includes ß1D integrin and is also concentrated at costameres.75 Direct interaction between integrins and the DGC has not been shown, but immunoprecipitation studies suggest bidirectional signaling between these complexes.76
|
|
Gene Expression Studies: Pathogenic Pathways Uncovered |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Similar to the biochemical and cell biological studies of the DGC, high-density DNA microarray technology has been applied to DGC mutant muscle to ascertain its common and unique features. Gene expression profiles of human and mouse muscle mutant for dystrophin or
-sarcoglycan documented net positive gene expression, consistent with an overwhelming inflammatory response in dystrophic muscle.77 Inflammatory disease load index showed a steep rise after postnatal day 14, peaking by day 56. Muscle from early-time-point (postnatal day 14) mdx mice showed net positive gene expression mainly reflecting genes implicated in energy and metabolism.78 Follow-up experiments identified small CC chemokines and a CC receptor as prominent in the inflammatory response, a finding correlated with immunocytochemical evidence of macrophage and T lymphocyte recruitment into dystrophic mdx muscle of the same age.79
Functional grouping of genes whose expression changed showed consistent upregulation of genes involved in calcium handling, including S100a calcium-binding proteins. Extracellular matrix genes were similarly upregulated, including procollagens, biglycan, matrix metalloproteases, and tenascin c. Genes implicated in muscle regeneration and myogenesis, including -cardiac actin, -actin, cardiac ankyrin repeat protein, cathepsins, and osteoblast-specific factor 2, showed an increase in expression. It is unclear whether these latter alterations represent functional regeneration or a pathologic persistent fetal gene program. It should be noted that the microarray format yielded results consistent with previous studies of dystrophic muscle.80–85 Many aspects of the 56-day-old mdx skeletal muscle expression profile display striking resemblance to the profile of regenerating skeletal muscle.86 The relative lack of inflammatory infiltrate coupled with the lack of an aggressive regenerative program are two of the important features that differ between the heart and skeletal muscle of DGC mutants.
A comparison of DMD and -sarcoglycan mutant muscle gene expression profiles was used to identify common features.87,88 Like the profiles from murine tissue, the net change in gene expression in these studies was positive. However, the number of differentially expressed genes associated with an inflammatory response was negligible. Genes associated with metabolism, energetics, and mitochondrial function were universally decreased, which the authors suggested may represent a metabolic crisis within human dystrophin-deficient skeletal muscle.87 Overall, gene expression profiles of dystrophin mutant versus -sarcoglycan mutant muscle biopsies were remarkably similar. Of the 20 genes identified as differentially regulated between these genetically distinct disorders, many were found differentially regulated in other microarray studies of Duchenne versus control skeletal muscle. Serum amyloid protein A, Her3, osteopontin, and c-fos were uniquely called within the -sarcoglycan group and not seen in other human studies. The significance of this observation is unclear but may reflect some of the unique differences conferred by individual sarcoglycan gene disruption.
|
Therapeutic Restoration of DGC: Stem Cell Transplantation |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
DGC mutants provide important models in which to test gene and stem cell therapies. Stem cell therapy relies on isogenic stem cells as a vehicle to deliver a normal allele to a mutant organism. As it applies to the muscular dystrophies, the ideal stem cell or its progeny would home to and engraft in regions of muscle damage, fuse to preexisting myofibers, differentiate to restore the missing protein, and, finally, improve muscle function. Over the past several years, there has been an evolution in this field in terms of the refinement of stem cell populations as well as a diversity of delivery methods. Primary myoblasts isolated from the muscle of neonatal mice and transplanted into mdx mice were the first successful stem cell transplants in the field.89,90 Although these results were promising, the search for more pluripotent, ancestral progenitors led to the isolation of additional stem cell populations from distinct tissue compartments, such as bone marrow and stroma, muscle, skin, and heart. Isolated from fetal, neonatal, or adult mice and using Hoechst dye exclusion or preplating techniques, stem cells have been frequently transplanted into the mdx mouse, because the ability to restore dystrophin protein expression provides a useful marker of successful transplantation.
Side population (SP) cells can be isolated from adult bone marrow and skeletal muscle by the ability to rapidly efflux Hoechst dye 33342.91 Cell surface markers on SP cells vary depending on their tissue of origin. Hematopoietic SPs are positive for c-kit, CD43, and CD45, whereas muscle-derived SPs are negative for these antigens. Despite these distinctions, systemic transplantation of male hematopoietic SPs or muscle-derived SPs into lethally irradiated female mdx resulted in restoration of limited dystrophin protein expression in skeletal muscle, and up to 0.5% of myofibers in the recipients were both donor-derived and expressed dystrophin.92 More recently, SPs have been isolated from the skin of adult mice. When normal male skin-derived SP cells were injected into the tail vein of nonirradiated female mdx mice, up to 0.2% of myofibers contained a donor-derived Y chromosome and dystrophin protein expression.93 Other SPs have been isolated from numerous tissues, including mammary epithelial cells, liver, and heart.94–96 The multidrug resistance pump ABCG2 has been implicated in the SP cell’s ability to extrude toxic dyes such as Hoechst 33342.97,98
Muscle-derived stem cells can be isolated from neonatal mouse muscle using a preplate technique in which nonadherent cells are enriched. Clones of these muscle-derived stem cells from mdx mice have been retrotransduced with a human mini-dystrophin gene expressing dystrophin and the stem cell markers CD34 and Sca-1. Transduced cells injected directly into the gastrocnemius muscle of mdx mice produced a low level of human dystrophin in recipient mice.99 Embryonic cells have also been tested in mouse DGC models. Mesangioblasts are vessel-associated stem cells isolated from fetal mice that can differentiate into most cell types of the mesoderm.100 Male mesangioblasts transplanted into female -sarcoglycan–null mice by a single femoral artery injection successfully engrafted and restored sarcoglycan protein expression and resulted in improved histopathology and decreased uptake of a vital dye in the treated leg.101 Stem cell transplantation in DGC mutant recipients provides an important forum in which to test the capabilities for both embryonic and adult stem cells. Future studies will be facilitated by the availability of these models to test stem cell regeneration for cardiomyopathy and in larger models such as the dystrophin-deficient canine model of DMD.
|
Therapeutic Restoration of DGC: Viral-Based Gene Therapy |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
Both high-capacity adenoviral and adeno-associated viral strategies have been successfully used to restore the DGC in skeletal muscle. The large size of dystrophin full-length cDNA (14 kb) combined with the 8-kb DNA cloning capacity of adenoviral vectors allowed investigators to test several truncated but not full-length forms of dystrophin in gene therapy approaches. These investigations showed promising results but only temporary dystrophin expression because of a virally induced immune response.102,103 Adenoviral vectors have been altered to increase cloning capacity and decrease the immune response. Full-length mouse dystrophin cDNA driven by the muscle creatine kinase promoter in a gutted adenovirus vector produced significant dystrophin expression, improved force production, a decrease in susceptibility to contraction-induced injury, and a low-level immune response.104
Recently, Yue et al105 reported using adenovirus-mediated therapy and a novel neonatal cardiac gene transfer technique to test expression of a micro-dystrophin gene in the hearts of mdx mice. A specialized cold chamber was used to anesthetize the mice and provide cold shock for the delivery of virus directly into the cardiac cavity. Shown by a human-specific antibody, the micro-dystrophin gene driven by the CMV promoter induced expression of dystrophin, ß-sarcoglycan, and ß-dystroglycan in cardiomyocytes. The expression of dystrophin also correlated with impermeability of that fiber to EBD after ß-isoproterenol challenge. The BIO14.6 Syrian hamster model of cardiomyopathy arises from a large deletion in the -sarcoglycan gene. Given the larger size of this animal model, viral gene therapy approaches have been more extensively used to demonstrate the success of gene therapy in cardiomyopathic hearts.106–111
|
Summary |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
The DGC is a critical complex for the maintenance of normal cardiac and skeletal muscle, although the function in these two muscle types may differ slightly. Overall, many of the main components, including dystrophin, dystroglycan, sarcoglycans, and syntrophins, may be similar in heart and skeletal muscle. However, some differences in the more peripheral aspects of the DGC may differ between these muscle types. Current efforts are directed at understanding the tissue-specific expression and function of the DGC and include studying the DGC complex in smooth, including vascular, muscle. The DGC is best thought of as a mechanosignaling complex with dual mechanical and nonmechanical membrane stabilizing functions. This dual functionality can also be ascribed to the sarcoglycan complex, because this complex itself displays both mechanical and signaling roles. The importance of this complex to human disease is now well established. DGC mutants provide excellent models in which to test both cell-based and viral-based gene therapy as well as models in which to study the pathogenesis of skeletal and cardiac power dysfunction.
|
Acknowledgments |
|---|
E.M.M. is supported by the NIH, the Muscular Dystrophy Association, and the Burroughs Wellcome Foundation and is an Established Investigator of the American Heart Association. K.A.L. is supported by an American Heart Association Predoctoral Award (Midwest Affiliate). R.K. is supported by the NIH.
|
Footnotes |
|---|
Original received December 5, 2003; resubmission received March 8, 2004; accepted March 16, 2004.
|
References |
|---|
|
TopAbstractIntroductionDystrophinDystrophin Has Four Functional...The Sarcoglycan Complex and...DystroglycanSyntrophin{alpha}-DystrobrevinCaveolin and NO SynthaseCostameric Arrangement of the...Gene Expression Studies:...Therapeutic Restoration of DGC:...Therapeutic Restoration of DGC:...SummaryReferences |
|---|
1. Feener CA, Koenig M, Kunkel LM. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature. 1989; 338: 509–511.[CrossRef][Medline] [Order article via Infotrieve]
2. Nobile C, Galvagni F, Marchi J, Roberts R, Vitiello L. Genomic organization of the human dystrophin gene across the major deletion hot spot and the 3' region. Genomics. 1995; 28: 97–100.[CrossRef][Medline] [Order article via Infotrieve]
3. Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics. 1993; 16: 536–538.[CrossRef][Medline] [Order article via Infotrieve]
4. Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddu A, Marrosu MG, Cianchetti C, Realdi G, Cao A, Melis MA. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med. 1993; 329: 921–925.
5. Milasin J, Muntoni F, Severini GM, Bartoloni L, Vatta M, Krajinovic M, Mateddu A, Angelini C, Camerini F, Falaschi A, Mestroni L, Giacca M. A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet. 1996; 5: 73–79.
6. Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation. 1997; 95: 2434–2440.
7. Feng J, Yan J, Buzin CH, Towbin JA, Sommer SS. Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab. 2002; 77: 119–126.[CrossRef][Medline] [Order article via Infotrieve]
8. Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res. 1993; 72: 349–360.
9. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology. 2003; 99: 1–19.[CrossRef][Medline] [Order article via Infotrieve]
10. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol. 2000; 150: 1209–1214.
11. Rybakova IN, Patel JR, Davies KE, Yurchenco PD, Ervasti JM. Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. Mol Biol Cell. 2002; 13: 1512–1521.
12. Ahn AH, Kunkel LM. Syntrophin binds to an alternatively spliced exon of dystrophin. J Cell Biol. 1995; 128: 363–371.
13. Suzuki A, Yoshida M, Ozawa E. Mammalian 1- and 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J Cell Biol. 1995; 128: 373–381.
14. Crosbie RH, Heighway J, Venzke DP, Lee JC, Campbell KP. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. J Biol Chem. 1997; 272: 31221–31224.
15. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993; 90: 3710–3714.
16. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, Petrof BJ. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 2001; 15: 1655–1657.
17. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989; 244: 1578–1580.
18. DiMario JX, Uzman A, Strohman RC. Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev Biol. 1991; 148: 314–321.[CrossRef][Medline] [Order article via Infotrieve]
19. Gillis JM. Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J Muscle Res Cell Motil. 1999; 20: 605–625.[CrossRef][Medline] [Order article via Infotrieve]
20. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem (Tokyo). 1995; 118: 959–964.
21. Straub V, Rafael JA, Chamberlain JS, Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997; 139: 375–385.
22. Stetson SJ, Perez-Verdia A, Vatta M, Bowles NE, Towbin JA, Torre-Amione G. Improved myocardial structure following LVAD support: effect of unloading on dystrophin expression. J Heart Lung Transplant. 2001; 20: 240.
23. Vatta M, Stetson SJ, Perez-Verdia A, Entman ML, Noon GP, Torre-Amione G, Bowles NE, Towbin JA. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 2002; 359: 936–941.[CrossRef][Medline] [Order article via Infotrieve]
24. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999; 5: 320–326.[CrossRef][Medline] [Order article via Infotrieve]
25. Xiong D, Lee GH, Badorff C, Dorner A, Lee S, Wolf P, Knowlton KU. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002; 8: 872–877.[Medline] [Order article via Infotrieve]
26. Hack AA, Ly CT, Jiang F, Clendenin CJ, Sigrist KS, Wollmann RL, McNally EM. -Sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol. 1998; 142: 1279–1287.
27. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, Straub V, Barresi R, Bansal D, Hrstka RF, Williamson R, Campbell KP. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 1999; 98: 465–474.[CrossRef][Medline] [Order article via Infotrieve]
28. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, Hadhazy MA, Hadhazy MR, Sweeney HL, McNally EM. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci. 2000; 113 (pt 14): 2535–2544.[Abstract]
29. Hack AA, Cordier L, Shoturma DI, Lam MY, Sweeney HL, McNally EM. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A. 1999; 96: 10723–10728.
30. Barresi R, Di Blasi C, Negri T, Brugnoni R, Vitali A, Felisari G, Salandi A, Daniel S, Cornelio F, Morandi L, Mora M. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by ß sarcoglycan mutations. J Med Genet. 2000; 37: 102–107.
31. Melacini P, Fanin M, Duggan DJ, Freda MP, Berardinelli A, Danieli GA, Barchitta A, Hoffman EP, Dalla Volta S, Angelini C. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve. 1999; 22: 473–479.[CrossRef][Medline] [Order article via Infotrieve]
32. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, Bowles NE, Towbin JA. Mutations in the human -sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest. 2000; 106: 655–662.[Medline]
[Order article via Infotrieve]
33. Jung D, Duclos F, Apostol B, Straub V, Lee JC, Allamand V, Venzke DP, Sunada Y, Moomaw CR, Leveille CJ, Slaughter CA, Crawford TO, McPherson JD, Campbell KP. Characterization of -sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy. J Biol Chem. 1996; 271: 32321–32329.
34. McNally EM, Duggan D, Gorospe JR, Bonnemann CG, Fanin M, Pegoraro E, Lidov HG, Noguchi S, Ozawa E, Finkel RS, Cruse RP, Angelini C, Kunkel LM, Hoffman EP. Mutations that disrupt the carboxyl-terminus of -sarcoglycan cause muscular dystrophy. Hum Mol Genet. 1996; 5: 1841–1847.
35. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP. Progressive muscular dystrophy in -sarcoglycan-deficient mice. J Cell Biol. 1998; 142: 1461–1471.
36. Liu LA, Engvall E. Sarcoglycan isoforms in skeletal muscle. J Biol Chem. 1999; 274: 38171–38176.
37. Zhu X, Wheeler MT, Hadhazy M, Lam MY, McNally EM. Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J. 2002; 16: 1096–1098.
38. Wheeler MT, Korcarz CE, Collins KA, Lapidos KA, Hack AA, Lyons MR, Zarnegar S, Earley JU, Lang RM, McNally EM. Secondary coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol. 2004; 164: 1063–1071.
39. Factor SM, Cho SH, Scheuer J, Sonnenblick EH, Malhotra A. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J Am Coll Cardiol. 1988; 12: 1599–1604.[Abstract]
40. Durbeej M, Cohn RD, Hrstka RF, Moore SA, Allamand V, Davidson BL, Williamson RA, Campbell KP. Disruption of the ß-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell. 2000; 5: 141–151.[CrossRef][Medline] [Order article via Infotrieve]
41. Wheeler MT, Allikian MJ, Heydemann A, Hadhazy M, Zarnegar S, McNally EM. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest. 2004; 113: 668–675.[CrossRef][Medline] [Order article via Infotrieve]
42. Cohn RD, Durbeej M, Moore SA, Coral-Vazquez R, Prouty S, Campbell KP. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest. 2001; 107: R1–R7.[Medline] [Order article via Infotrieve]
43. Crosbie RH, Lebakken CS, Holt KH, Venzke DP, Straub V, Lee JC, Grady RM, Chamberlain JS, Sanes JR, Campbell KP. Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex. J Cell Biol. 1999; 145: 153–165.
44. Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, Wakabayashi-Takai E, Noguchi S, Sasaoka T, Ozawa E. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet. 2000; 9: 1033–1040.
45. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 2000; 150: 1399–1410.
46. Lebakken CS, Venzke DP, Hrstka RF, Consolino CM, Faulkner JA, Williamson RA, Campbell KP. Sarcospan-deficient mice maintain normal muscle function. Mol Cell Biol. 2000; 20: 1669–1677.
47. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003; 19: 397–422.[CrossRef][Medline] [Order article via Infotrieve]
48. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol. 1999; 11: 602–607.[CrossRef][Medline] [Order article via Infotrieve]
49. Yang B, Jung D, Motto D, Meyer J, Koretzky G, Campbell KP. SH3 domain-mediated interaction of dystroglycan and Grb2. J Biol Chem. 1995; 270: 11711–11714.
50. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, Macioce P, Sargiacomo M, Bricarelli FD, Minetti C, Sudol M, Lisanti MP. Caveolin-3 directly interacts with the C-terminal tail of ß-dystroglycan: identification of a central WW-like domain within caveolin family members. J Biol Chem. 2000; 275: 38048–38058.
51. Campbell KP, Stull JT. Skeletal muscle basement membrane-sarcolemma-cytoskeleton interaction minireview series. J Biol Chem. 2003; 278: 12599–12600.
52. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, Herrmann R, Anderson LV, Bashir R, Burgunder JM, Fallet S, Romero N, Fardeau M, Straub V, Storey G, Pollitt C, Richard I, Sewry CA, Bushby K, Voit T, Blake DJ, Muntoni F. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet. 2001; 10: 2851–2859.
53. Kramarcy NR, Vidal A, Froehner SC, Sealock R. Association of utrophin and multiple dystrophin short forms with the mammalian Mr 58,000 dystrophin-associated protein (syntrophin). J Biol Chem. 1994; 269: 2870–2876.
54. Peters MF, Kramarcy NR, Sealock R, Froehner SC. ß2-Syntrophin: localization at the neuromuscular junction in skeletal muscle. Neuroreport. 1994; 5: 1577–1580.[Medline] [Order article via Infotrieve]
55. Chockalingam PS, Gee SH, Jarrett HW. Pleckstrin homology domain 1 of mouse 1-syntrophin binds phosphatidylinositol 4,5-bisphosphate. Biochemistry. 1999; 38: 5596–5602.[CrossRef][Medline]
[Order article via Infotrieve]
56. Gibson TJ, Hyvonen M, Musacchio A, Saraste M, Birney E. PH domain: the first anniversary. Trends Biochem Sci. 1994; 19: 349–353.[CrossRef][Medline] [Order article via Infotrieve]
57. Madhavan R, Massom LR, Jarrett HW. Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem Biophys Res Commun. 1992; 185: 753–759.[CrossRef][Medline] [Order article via Infotrieve]
58. Oak SA, Russo K, Petrucci TC, Jarrett HW. Mouse 1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. 2001; 40: 11270–11278.[CrossRef][Medline]
[Order article via Infotrieve]
59. Oak SA, Zhou YW, Jarrett HW. Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1. J Biol Chem. 2003; 278: 39287–39295.
60. Blake DJ. Dystrobrevin dynamics in muscle-cell signalling: a possible target for therapeutic intervention in Duchenne muscular dystrophy? Neuromuscul Disord. 2002; 12 (suppl 1): S110–S117.[CrossRef][Medline] [Order article via Infotrieve]
61. Roberts RG. Dystrophins and dystrobrevins. Genome Biol. 2001; 2: REVIEWS3006.[Medline] [Order article via Infotrieve]
62. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, Sanes JR. Role for -dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol. 1999; 1: 215–220.[CrossRef][Medline]
[Order article via Infotrieve]
63. Hamamichi Y, Ichida F, Hashimoto I, Uese KH, Miyawaki T, Tsukano S, Ono Y, Echigo S, Kamiya T. Isolated noncompaction of the ventricular myocardium: ultrafast computed tomography and magnetic resonance imaging. Int J Cardiovasc Imaging. 2001; 17: 305–314.[CrossRef][Medline] [Order article via Infotrieve]
64. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, Miyawaki T, Dreyer WJ, Messina J, Li H, Bowles NE, Towbin JA. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation. 2001; 103: 1256–1263.
65. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells: caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160–15165.
66. Smythe GM, Eby JC, Disatnik MH, Rando TA. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci. 2003; 116: 4739–4749.
67. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995; 82: 743–752.[CrossRef][Medline] [Order article via Infotrieve]
68. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2000; 97: 13818–13823.
69. Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, Adams ME. Vasomodulation by skeletal muscle-derived nitric oxide requires -syntrophin–mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ Res. 2003; 92: 554–560.
70. Heydemann A, Huber JM, Kakkar R, Wheeler MT, McNally EM. Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol. 2004; 36: 213–223.[CrossRef][Medline] [Order article via Infotrieve]
71. Minetti C, Beltrame F, Marcenaro G, Bonilla E. Dystrophin at the plasma membrane of human muscle fibers shows a costameric localization. Neuromuscul Disord. 1992; 2: 99–109.[CrossRef][Medline] [Order article via Infotrieve]
72. Williams MW, Bloch RJ. Differential distribution of dystrophin and ß-spectrin at the sarcolemma of fast twitch skeletal muscle fibers. J Muscle Res Cell Motil. 1999; 20: 383–393.[CrossRef][Medline] [Order article via Infotrieve]
73. Danowski BA, Imanaka-Yoshida K, Sanger JM, Sanger JW. Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. J Cell Biol. 1992; 118: 1411–1420.
74. Minetti C, Cordone G, Beltrame F, Bado M, Bonilla E. Disorganization of dystrophin costameric lattice in Becker muscular dystrophy. Muscle Nerve. 1998; 21: 211–216.[CrossRef][Medline] [Order article via Infotrieve]
75. Belkin AM, Zhidkova NI, Balzac F, Altruda F, Tomatis D, Maier A, Tarone G, Koteliansky VE, Burridge K. ß1D integrin displaces the ß1A isoform in striated muscles: localization at junctional structures and signaling potential in nonmuscle cells. J Cell Biol. 1996; 132: 211–226.
76. Yoshida T, Pan Y, Hanada H, Iwata Y, Shigekawa M. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J Biol Chem. 1998; 273: 1583–1590.
77. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Guo W, Andrade FH. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002; 11: 263–272.
78. Porter JD, Merriam AP, Leahy P, Gong B, Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet. 2003; 12: 1813–1821.
79. Porter JD, Guo W, Merriam AP, Khanna S, Cheng G, Zhou X, Andrade FH, Richmonds C, Kaminski HJ. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord. 2003; 13: 223–235.[CrossRef][Medline] [Order article via Infotrieve]
80. Ordahl CP. The skeletal and cardiac -actin genes are coexpressed in early embryonic striated muscle. Dev Biol. 1986; 117: 488–492.[CrossRef][Medline]
[Order article via Infotrieve]
81. Selbert S, Fischer P, Menke A, Jockusch H, Pongratz D, Noegel AA. Annexin VII relocalization as a result of dystrophin deficiency. Exp Cell Res. 1996; 222: 199–208.[CrossRef][Medline] [Order article via Infotrieve]
82. Settles DL, Cihak RA, Erickson HP. Tenascin-C expression in dystrophin-related muscular dystrophy. Muscle Nerve. 1996; 19: 147–154.[CrossRef][Medline] [Order article via Infotrieve]
83. Bowe MA, Mendis DB, Fallon JR. The small leucine-rich repeat proteoglycan biglycan binds to -dystroglycan and is upregulated in dystrophic muscle. J Cell Biol. 2000; 148: 801–810.
84. Fang J, Shi GP, Vaghy PL. Identification of the increased expression of monocyte chemoattractant protein-1, cathepsin S, UPIX-1, and other genes in dystrophin-deficient mouse muscles by suppression subtractive hybridization. J Cell Biochem. 2000; 79: 164–172.[CrossRef][Medline] [Order article via Infotrieve]
85. Nakada C, Tsukamoto Y, Oka A, Nonaka I, Takeda S, Sato K, Mori S, Ito H, Moriyama M. Cardiac-restricted ankyrin-repeated protein is differentially induced in Duchenne and congenital muscular dystrophy. Lab Invest. 2003; 83: 711–719.[Medline] [Order article via Infotrieve]
86. Goetsch SC, Hawke TJ, Gallardo TD, Richardson JA, Garry DJ. Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol Genomics. 2003; 14: 261–271.
87. Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000; 151: 1321–1336.
88. Borup RH, Toppo S, Chen YW, Teslovich TM, Lanfranchi G, Valle G, Hoffman EP. Development and production of an oligonucleotide MuscleChip: use for validation of ambiguous ESTs. BMC Bioinformatics. 2002; 3: 33.[CrossRef][Medline] [Order article via Infotrieve]
89. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 1994; 125: 1275–1287.
90. Morgan JE, Partridge TA. Cell transplantation and gene therapy in muscular dystrophy. Bioessays. 1992; 14: 641–645.[CrossRef][Medline] [Order article via Infotrieve]
91. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996; 183: 1797–1806.
92. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, Kunkel LM, Mulligan RC. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999; 401: 390–394.[CrossRef][Medline] [Order article via Infotrieve]
93. Montanaro F, Liadaki K, Volinski J, Flint A, Kunkel LM. Skeletal muscle engraftment potential of adult mouse skin side population cells. Proc Natl Acad Sci U S A. 2003; 100: 9336–9341.
94. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol. 2002; 245: 42–56.[CrossRef][Medline] [Order article via Infotrieve]
95. Uchida N, Leung FY, Eaves CJ. Liver and marrow of adult mdr-1a/1b–/– mice show normal generation, function, and multi-tissue trafficking of primitive hematopoietic cells. Exp Hematol. 2002; 30: 862–869.[CrossRef][Medline] [Order article via Infotrieve]
96. Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett. 2002; 530: 239–243.[CrossRef][Medline] [Order article via Infotrieve]
97. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002; 99: 507–512.
98. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001; 7: 1028–1034.[CrossRef][Medline] [Order article via Infotrieve]
99. Ikezawa M, Cao B, Qu Z, Peng H, Xiao X, Pruchnic R, Kimura S, Miike T, Huard J. Dystrophin delivery in dystrophin-deficient DMD(mdx) skeletal muscle by isogenic muscle-derived stem cell transplantation. Hum Gene Ther. 2003; 14: 1535–1546.[CrossRef][Medline] [Order article via Infotrieve]
100. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, Caprioli A, Sirabella D, Baiocchi M, De Maria R, Boratto R, Jaffredo T, Broccoli V, Bianco P, Cossu G. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development. 2002; 129: 2773–2783.
101. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D’Antona G, Pellegrino MA, Barresi R, Bresolin N, De Angelis MG, Campbell KP, Bottinelli R, Cossu G. Cell therapy of -sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 2003; 301: 487–492.
102. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994; 91: 4407–4411.
103. Acsadi G, Lochmuller H, Jani A, Huard J, Massie B, Prescott S, Simoneau M, Petrof BJ, Karpati G. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther. 1996; 7: 129–140.[Medline] [Order article via Infotrieve]
104. DelloRusso C, Scott JM, Hartigan-O’Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, Chamberlain JS. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci U S A. 2002; 99: 12979–12984.
105. Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation. 2003; 108: 1626–1632.
106. Ikeda Y, Gu Y, Iwanaga Y, Hoshijima M, Oh SS, Giordano FJ, Chen J, Nigro V, Peterson KL, Chien KR, Ross J Jr. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation. 2002; 105: 502–508.
107. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK, Mercier IM, Desjardins PR, Mitchell MA, Zheng XG, Leferovich J, Gao GP, Balice-Gordon RJ, Wilson JM, Stedman HH. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999; 5: 439–443.[CrossRef][Medline] [Order article via Infotrieve]
108. Holt KH, Lim LE, Straub V, Venzke DP, Duclos F, Anderson RD, Davidson BL, Campbell KP. Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using -sarcoglycan gene transfer. Mol Cell. 1998; 1: 841–848.[CrossRef][Medline]
[Order article via Infotrieve]
109. Li J, Dressman D, Tsao YP, Sakamoto A, Hoffman EP, Xiao X. rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther. 1999; 6: 74–82.[CrossRef][Medline] [Order article via Infotrieve]
110. Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol. 2000; 74: 1436–1442.
111. Kawada T, Sakamoto A, Nakazawa M, Urabe M, Masuda F, Hemmi C, Wang Y, Shin WS, Nakatsuru Y, Sato H, Ozawa K, Toyo-oka T. Morphological and physiological restorations of hereditary form of dilated cardiomyopathy by somatic gene therapy. Biochem Biophys Res Commun. 2001; 284: 431–435.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. P. Millay, S. A. Goonasekera, M. A. Sargent, M. Maillet, B. J. Aronow, and J. D. Molkentin Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism PNAS, November 10, 2009; 106(45): 19023 - 19028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Millay, M. Maillet, J. A. Roche, M. A. Sargent, E. M. McNally, R. J. Bloch, and J. D. Molkentin Genetic Manipulation of Dysferlin Expression in Skeletal Muscle: Novel Insights into Muscular Dystrophy Am. J. Pathol., November 1, 2009; 175(5): 1817 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pilichou, C. A. Remme, C. Basso, M. E. Campian, S. Rizzo, P. Barnett, B. P. Scicluna, B. Bauce, M. J.B. van den Hoff, J. M.T. de Bakker, et al. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy J. Exp. Med., August 3, 2009; 206(8): 1787 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Muller The monogenic primary dystonias Brain, August 1, 2009; 132(8): 2005 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Goehringer, D. Rutschow, R. Bauer, S. Schinkel, D. Weichenhan, R. Bekeredjian, V. Straub, J. A. Kleinschmidt, H. A. Katus, and O. J. Muller Prevention of cardiomyopathy in {delta}-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors Cardiovasc Res, June 1, 2009; 82(3): 404 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zheng, H. Cheng, X. Li, J. Zhang, L. Cui, K. Ouyang, L. Han, T. Zhao, Y. Gu, N. D. Dalton, et al. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death Hum. Mol. Genet., February 15, 2009; 18(4): 701 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Hess, W. McKenna, and H.-P. Schultheiss CHAPTER 18 Myocardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stum, E. Girard, M. Bangratz, V. Bernard, M. Herbin, A. Vignaud, A. Ferry, C.-S. Davoine, A. Echaniz-Laguna, F. Rene, et al. Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia Hum. Mol. Genet., October 15, 2008; 17(20): 3166 - 3179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Q. Wallace, K. A. Lapidos, J. S. Kenik, and E. M. McNally Long-Term Survival of Transplanted Stem Cells in Immunocompetent Mice with Muscular Dystrophy Am. J. Pathol., September 1, 2008; 173(3): 792 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bauer, G.A. MacGowan, A. Blain, K. Bushby, and V. Straub Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy Cardiovasc Res, September 1, 2008; 79(4): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M McNally Duchenne muscular dystrophy: how bad is the heart? Heart, August 1, 2008; 94(8): 976 - 977. [Full Text] [PDF]
|
|
|
|
|
|
S. Gastaldello, S. D'Angelo, S. Franzoso, M. Fanin, C. Angelini, R. Betto, and D. Sandona Inhibition of Proteasome Activity Promotes the Correct Localization of Disease-Causing {alpha}-Sarcoglycan Mutants in HEK-293 Cells Constitutively Expressing {beta}-, {gamma}-, and {delta}-Sarcoglycan Am. J. Pathol., July 1, 2008; 173(1): 170 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, A. de Morree, A. van Remoortere, K. Bushby, R. R. Frants, J. T. Dunnen, and S. M. van der Maarel Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle Hum. Mol. Genet., June 15, 2008; 17(12): 1855 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Thomas, G. L. Joseph, T. D. Adkins, F. H. Andrade, and J. C. Stemple Laryngeal Muscles Are Spared in the Dystrophin Deficient mdx Mouse J Speech Lang Hear Res, June 1, 2008; 51(3): 586 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Elsherif, M. S. Huang, S.-Y. Shai, Y. Yang, R. Y. Li, J. Chun, M. A. Mekany, A. L. Chu, S. J. Kaufman, and R. S. Ross Combined Deficiency of Dystrophin and {beta}1 Integrin in the Cardiac Myocyte Causes Myocardial Dysfunction, Fibrosis and Calcification Circ. Res., May 9, 2008; 102(9): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Fradkin, R. A. Baines, M. C. van der Plas, and J. N. Noordermeer The Dystrophin Dp186 Isoform Regulates Neurotransmitter Release at a Central Synapse in Drosophila J. Neurosci., May 7, 2008; 28(19): 5105 - 5114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bartoli, E. Gicquel, L. Barrault, T. Soheili, M. Malissen, B. Malissen, N. Vincent-Lacaze, N. Perez, B. Udd, O. Danos, et al. Mannosidase I inhibition rescues the human {alpha}-sarcoglycan R77C recurrent mutation Hum. Mol. Genet., May 1, 2008; 17(9): 1214 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Reynolds, S. A. McCalmon, J. A. Donaghey, and F. J. Naya Deregulated Protein Kinase A Signaling and Myospryn Expression in Muscular Dystrophy J. Biol. Chem., March 28, 2008; 283(13): 8070 - 8074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, D. J. Burkin, and S. J. Kaufman Increasing {alpha}7{beta}1-integrin promotes muscle cell proliferation, adhesion, and resistance to apoptosis without changing gene expression Am J Physiol Cell Physiol, February 1, 2008; 294(2): C627 - C640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sharma, T. Tran, G. L. Stelmack, K. McNeill, R. Gosens, M. M. Mutawe, H. Unruh, W. T. Gerthoffer, and A. J. Halayko Expression of the dystrophin-glycoprotein complex is a marker for human airway smooth muscle phenotype maturation Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L57 - L68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Allikian, G. Bhabha, P. Dospoy, A. Heydemann, P. Ryder, J. U. Earley, M. J. Wolf, H. A. Rockman, and E. M. McNally Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants Hum. Mol. Genet., December 1, 2007; 16(23): 2933 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kandert, Y. Luke, T. Kleinhenz, S. Neumann, W. Lu, V. M. Jaeger, M. Munck, M. Wehnert, C. R. Muller, Z. Zhou, et al. Nesprin-2 giant safeguards nuclear envelope architecture in LMNA S143F progeria cells Hum. Mol. Genet., December 1, 2007; 16(23): 2944 - 2959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Haines, S. Seabrooke, and B. A. Stewart Dystroglycan and Protein O-Mannosyltransferases 1 and 2 Are Required to Maintain Integrity of Drosophila Larval Muscles Mol. Biol. Cell, December 1, 2007; 18(12): 4721 - 4730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Yatsenko, E. E. Gray, H. R. Shcherbata, L. B. Patterson, V. D. Sood, M. M. Kucherenko, D. Baker, and H. Ruohola-Baker A Putative Src Homology 3 Domain Binding Motif but Not the C-terminal Dystrophin WW Domain Binding Motif Is Required for Dystroglycan Function in Cellular Polarity in Drosophila J. Biol. Chem., May 18, 2007; 282(20): 15159 - 15169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Parsons, D. P. Millay, M. A. Sargent, F. J. Naya, E. M. McNally, H. L. Sweeney, and J. D. Molkentin Genetic Disruption of Calcineurin Improves Skeletal Muscle Pathology and Cardiac Disease in a Mouse Model of Limb-Girdle Muscular Dystrophy J. Biol. Chem., March 30, 2007; 282(13): 10068 - 10078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hnia, G. Hugon, F. Rivier, A. Masmoudi, J. Mercier, and D. Mornet Modulation of p38 Mitogen-Activated Protein Kinase Cascade and Metalloproteinase Activity in Diaphragm Muscle in Response to Free Radical Scavenger Administration in Dystrophin-Deficient Mdx Mice Am. J. Pathol., February 1, 2007; 170(2): 633 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fiaccavento, F. Carotenuto, M. Minieri, L. Masuelli, A. Vecchini, R. Bei, A. Modesti, L. Binaglia, A. Fusco, A. Bertoli, et al. {alpha}-Linolenic Acid-Enriched Diet Prevents Myocardial Damage and Expands Longevity in Cardiomyopathic Hamsters Am. J. Pathol., December 1, 2006; 169(6): 1913 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Rice, D. L. Preston, D. Neff, M. Norton, and E. R. Blough Age-Related Dystrophin-Glycoprotein Complex Structure and Function in the Rat Extensor Digitorum Longus and Soleus Muscle J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2006; 61(11): 1119 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Ellinor, S. Sasse-Klaassen, S. Probst, B. Gerull, J. T. Shin, A. Toeppel, A. Heuser, B. Michely, D. M. Yoerger, B.-S. Song, et al. A Novel Locus for Dilated Cardiomyopathy, Diffuse Myocardial Fibrosis, and Sudden Death on Chromosome 10q25-26 J. Am. Coll. Cardiol., July 4, 2006; 48(1): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Chakkalakal, S. A. Michel, E. R. Chin, R. N. Michel, and B. J. Jasmin Targeted inhibition of Ca2+/calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle Hum. Mol. Genet., May 1, 2006; 15(9): 1423 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hoshijima Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1313 - H1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Barton Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle Am J Physiol Cell Physiol, February 1, 2006; 290(2): C411 - C419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Colan Evolving Therapeutic Strategies for Dystrophinopathies: Potential for Conflict Between Cardiac and Skeletal Needs Circulation, November 1, 2005; 112(18): 2756 - 2758. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Stone, A. O'Neill, D. Catino, and R. J. Bloch Specific Interaction of the Actin-binding Domain of Dystrophin with Intermediate Filaments Containing Keratin 19 Mol. Biol. Cell, September 1, 2005; 16(9): 4280 - 4293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Epstein and M. S. Parmacek Recent Advances in Cardiac Development With Therapeutic Implications for Adult Cardiovascular Disease Circulation, July 26, 2005; 112(4): 592 - 597. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kislinger, A. O. Gramolini, Y. Pan, K. Rahman, D. H. MacLennan, and A. Emili Proteome Dynamics during C2C12 Myoblast Differentiation Mol. Cell. Proteomics, July 1, 2005; 4(7): 887 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Barth, S. Merk, E. Arnoldi, L. Zwermann, P. Kloos, M. Gebauer, K. Steinmeyer, M. Bleich, S. Kaab, M. Hinterseer, et al. Reprogramming of the Human Atrial Transcriptome in Permanent Atrial Fibrillation: Expression of a Ventricular-Like Genomic Signature Circ. Res., May 13, 2005; 96(9): 1022 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Dominov, A. J. Kravetz, M. Ardelt, C. A. Kostek, M. L. Beermann, and J. B. Miller Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice Hum. Mol. Genet., April 15, 2005; 14(8): 1029 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baudet Pathophysiology of heart failure: more bricks in the "crumbling sarcolemmal scaffolding" paradigm? Cardiovasc Res, February 1, 2005; 65(2): 299 - 301. [Full Text] [PDF]
|
|
|
|
|
|
A. Heydemann and E. M. McNally Regenerating More Than Muscle in Muscular Dystrophy Circulation, November 23, 2004; 110(21): 3290 - 3292. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||